UBT37034是一款新型多肽类受体激动剂，可通过选择性作用于神经肽Y2受体减轻体重。临床前多种动 物模型研究结果显示，UBT37034与GLP-1类似物联用能够显著降低体重。此外，UBT37034注射液关于 超重或肥胖适应症的新药临床试验申请("IND")已于2025年7月获得美国食品药品监督管理局批准，IND 编号为175188。未来，公司将持续致力于新产品研发，并重点提升在生物医药行业的竞争力及创造力， 预期将为公司及其股东创造更大收益。 格隆汇9月30日丨联邦制药(03933.HK)发布公告，2025年9月29日，公司全资附属公司联邦生物科技(珠 海横琴)有限公司自主研发的1类创新药注射用UBT37034关于超重或肥胖适应症的临床试验注册申请获 得中国国家药品监督管理局临床试验默示许可，受理号为CXHL2500772。 ...

Core Viewpoint - Federal Pharmaceutical (03933) has received implied approval for clinical trials of its injectable drug UBT37034 for overweight or obesity indications from the National Medical Products Administration of China [1] Group 1: Drug Development - UBT37034 is a novel peptide receptor agonist that selectively targets neuropeptide Y2 receptors to aid in weight loss [1] - Preclinical studies in various animal models indicate that UBT37034, when used in conjunction with GLP-1 analogs, significantly reduces body weight [1] - The new drug clinical trial application (IND) for UBT37034 regarding overweight or obesity indications was approved by the U.S. Food and Drug Administration on July 2025, with IND number 175188 [1] Group 2: Future Outlook - The company will continue to focus on new product development and aims to enhance its competitiveness and creativity in the biopharmaceutical industry [1] - The anticipated advancements are expected to generate greater returns for the company and its shareholders [1]

Core Viewpoint - Federal Pharmaceutical (03933) announced that its wholly-owned subsidiary, Federal Biotech (Zhuhai Hengqin) Co., Ltd., received implicit approval from the National Medical Products Administration of China for the clinical trial registration application of its innovative drug UBT37034 for overweight or obesity indications [1] Group 1: Product Development - UBT37034 is a novel peptide receptor agonist that selectively targets neuropeptide Y2 receptors to aid in weight reduction [1] - Preclinical studies in various animal models indicate that UBT37034, when used in conjunction with GLP-1 analogs, significantly reduces body weight [1] - The new drug clinical trial application (IND) for UBT37034 regarding overweight or obesity indications was approved by the U.S. Food and Drug Administration in July 2025, with IND number 175188 [1] Group 2: Future Outlook - The company will continue to focus on new product development and aims to enhance its competitiveness and creativity in the biopharmaceutical industry [1] - The anticipated advancements in product development are expected to generate greater returns for the company and its shareholders [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因依賴該等內 容而引致的任何損失承擔任何責任。 The United Laboratories International Holdings Limited 聯邦制藥國際控股有限公司 本公告乃由聯邦制藥國際控股有限公司（「本公司」）自願發出。 本公司董事會欣然公佈，於二零二五年九月二十九日，本公司全資附屬公司聯邦生物科技 （珠海橫琴）有限公司自主研發的 1 類創新藥注射用 UBT37034 關於超重或肥胖適應症的 臨 床 試 驗 註 冊 申 請 獲 得 中 國 國 家 藥 品 監 督 管 理 局 臨 床 試 驗 默 示 許 可 ， 受 理 號 為 CXHL2500772。 UBT37034 是一款新型多肽類受體激動劑，可通過選擇性作用於神經肽 Y2 受體減輕體重。 臨床前多種動物模型研究結果顯示，UBT37034 與 GLP-1 類似物聯用能夠顯著降低體重。 此外，UBT37034 注射液關於超重或肥胖適應症的新藥臨床試驗申請（「IND」）已於二零二 ...